ALVO OAKTREE ACQUISITION CORP II

Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in Alvotech at ISK 1,260 per share, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. The date of the transaction is May 20, 2025. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%).

Attachment



EN
23/05/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Bi...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva P...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Bi...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances  REYKJAVIK, ICELAND & TEL AVIV, ISRAEL & PARSIPPANY, NJ (December 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Indust...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea ...

Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026 Alvotech (NASDAQ: ALVO) og Teva Pharmaceuticals, bandarískt dótturfyrirtæki Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), hafa náð samningi við Regeneron Pharmaceuticals sem veitir Alvotech og Teva heimild til að markaðssetja AVT06, hliðstæðu við líftæknilyfið Eylea (aflibercept), í Bandaríkjunum. Samkvæmt samningnum getur sala hliðstæðunnar hafist í Bandaríkjunum á fjórða ársfjórðungi 2026, eða fyrr að ákveðnum skilyrðum uppfylltum. „Við höfum nýlega hlo...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech Successfully Places USD 108 Million Senior Unsecured Converti...

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. REYKJAVIK, ...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breyt...

Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara REYKJAVÍK (17. DESEMBER 2025) - Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið hefði selt breytanleg skuldabréf að fjárhæð 108 milljónir bandaríkjadala til hóps um 20 alþjóðlegra fjárfesta í lokuðu útboði. Mikil umframeftirspurn var eftir bréfum í útboðinu. Fjármögnunin styður við fjárfestingu félagsins í þróun nýrra hliðstæðna líftæknilyfja, sem áætlað er að verði um 250 milljónir bandaríkjadala á næsta ári. Félagið er nú að þróa 30 hliðstæður líftækn...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch